Our results indicate that αV-integrin expressed by cardiac PW1+ cells activate latent TGFβ and that the pharmacological blockade of αV-integrin could reduce TGFβ activation in vitro and cardiac fibrosis post-MI in vivo. The gene discussed is TGFB1; the disease is myocardial infarction.